Sign up to save your podcasts
Or
Share The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents.
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
View all episodes
By VJHemOnc
4.5
22 ratings
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents.
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
More shows like VJHemOnc Podcast
View all
TED Talks Daily
11,203 Listeners
Hematologic Oncology Update
70 Listeners
The Daily
111,034 Listeners
Up First from NPR
55,949 Listeners
OncoPharm
183 Listeners
Treating Blood Cancers
11 Listeners
blooducation's podcast
4 Listeners
Blood Podcast
55 Listeners
Healthcare Unfiltered
136 Listeners
The Ezra Klein Show
15,514 Listeners
The BSH Guidelines Official Podcast
2 Listeners
EHA Unplugged
1 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners
The HemOnc Pulse
26 Listeners